Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Mark G. Ward"'
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 11 (2018)
The introduction of vedolizumab, a lymphocyte adhesion inhibitor, has expanded the relatively limited therapeutic armamentarium available for Crohn’s disease and ulcerative colitis. Despite its effectiveness, both primary nonresponse and secondary
Externí odkaz:
https://doaj.org/article/473dfe7b15454f999326963175557470
Autor:
Jonathan P Segal, Mayur Garg, Miles P Sparrow, Gareth J Walker, Ashish Srinivasan, Peter De Cruz, Desmond Chee, Alex Boussioutas, Robert V Bryant, Georgina Hold, Gregory T Moore, Susan J Connor, Robert D Little, Mark G Ward, Jo McKenzie, Patrick Hilley, Robert B Gilmore, Manjeet Sandhu, Daniel Saitta, Elizabeth Chow, Lena Thin, Kate Lynch, Jane Andrews, Yoon K An, Emily K Wright
Publikováno v:
BMJ Open, Vol 14, Iss 7 (2024)
Introduction A substantial proportion of patients with inflammatory bowel disease (IBD) on intravenous infliximab require dose intensification. Accessing additional intravenous infliximab is labour-intensive and expensive, depending on insurance and
Externí odkaz:
https://doaj.org/article/c6f1e2d43a834509bfe7e3af4a9f737f
Autor:
Peter R Gibson, Miles P Sparrow, Fan Zhang, Georgina L Hold, Alex Boussioutas, Susan J Connor, Robert D Little, Thisun Jayawardana, Sabrina Koentgen, Mark G Ward
Publikováno v:
eGastroenterology, Vol 2, Iss 1 (2024)
The pathogenesis of inflammatory bowel disease (IBD) is complex and multifactorial. Undertreated disease has substantial individual and societal consequences. Current patient classification and subsequent positioning of IBD therapy are based on crude
Externí odkaz:
https://doaj.org/article/e7dbfb915d5640beb659756b18fe8572
Publikováno v:
Therapeutic Drug Monitoring. 43:692-695
Background The optimal use of infliximab depends on the measurement of trough levels with subsequent appropriate dose adjustment. With the introduction of biosimilars, it is important to demonstrate that the biosimilar behaves similarly in the assay
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91d1e0caeea1cd339845c2ec8e963676
https://doi.org/10.1097/ftd.0000000000000866
https://doi.org/10.1097/ftd.0000000000000866
Autor:
Robert D. Little, Mark G. Ward, Emily Wright, Asha J. Jois, Alex Boussioutas, Georgina L. Hold, Peter R. Gibson, Miles P. Sparrow
Publikováno v:
Journal of clinical medicine. 11(20)
CT-P13 is the first subcutaneous infliximab molecule approved for the management of inflammatory bowel disease (IBD). Compared to intravenous therapy, SC infliximab offers a range of practical, micro- and macroeconomic advantages. Data from the rheum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db5bf05f26c5f225e6f2d0c551d2e7a3
https://pubmed.ncbi.nlm.nih.gov/36294494
https://pubmed.ncbi.nlm.nih.gov/36294494
Autor:
Clarissa A. Rentsch, Mark G. Ward, Raphael P. Luber, Kirstin M. Taylor, David J. Gibson, Belinda Headon, Ourania Rosella, Heidi Y. Su, Antony B. Friedman, Michael Dooley, Miles P. Sparrow, Peter R. Gibson
Publikováno v:
Therapeutic drug monitoring.
Therapeutic monitoring of infliximab is limited by the time lag between drug-level measurement and dose adjustment, along with the cost of dose escalation. Strategies for dose reduction in stable patients on maintenance infliximab at supratherapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58d438167faa9f2319c0522ca1871c95
https://pubmed.ncbi.nlm.nih.gov/36174193
https://pubmed.ncbi.nlm.nih.gov/36174193
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::049ecc52ea07a9c7b4b7a3a91633a79c
https://pubmed.ncbi.nlm.nih.gov/36155249
https://pubmed.ncbi.nlm.nih.gov/36155249
Publikováno v:
Digestive Diseases and Sciences. 67:259-262
Data on outcomes following de-escalation of intensified anti-TNF therapy in inflammatory bowel disease (IBD) are limited and concerns about relapse limit willingness to de-escalate. To evaluate rates of successful de-escalation at 12 months and to de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6067c7d82b076fd3173c1f15edcbcba2
https://doi.org/10.1007/s10620-021-06937-z
https://doi.org/10.1007/s10620-021-06937-z
Autor:
Steven J. Brown, Edward Shelton, Damian Dowling, Soleiman Kashkooli, Emily K Wright, Britt Christensen, Emma Flanagan, Gregory T. Moore, Sally Bell, Katerina V Kiburg, Mark G. Ward, William Connell, Miles P. Sparrow, Michael A. Kamm, Peter De Cruz, Alyson L Ross, Alexander J. Thompson
Publikováno v:
Inflammatory Bowel Diseases. 27:1909-1918
Background There is considerable interest in improving the education and care of women with inflammatory bowel disease (IBD) to improve pregnancy outcomes. Despite increased awareness, not all women with IBD have access to pregnancy-related education
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2da7740e7d18eb99405b9480865ae00
https://doi.org/10.1093/ibd/izab021
https://doi.org/10.1093/ibd/izab021
Autor:
Mark G. Ward, Jane G. Muir, Antony B. Friedman, Peter R. Gibson, Jacqueline Susanne Barrett, Rebecca E. Burgell, Kirstin M. Taylor, Chu K Yao
Publikováno v:
Journal of Gastroenterology and Hepatology. 36:1580-1589
BACKGROUND AND AIM Limited data are available on the effects of fermentable fiber in altering intestinal pH and transit to predict efficacy-based delivery profiles of pH-dependent mesalamine coatings in ulcerative colitis (UC). This study aimed to ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8eb3936d203f4a4ffcf7e1c9abbc288e
https://doi.org/10.1111/jgh.15311
https://doi.org/10.1111/jgh.15311